Research

Intrexon and innovation are synonymous. We continue to invest in applied research related to our technology platform and related capabilities.


Current research initiatives include:
  • Gene Switches – Our RheoSwitch® technology is UltraVector-enabled, which allows us to rapidly design, test and optimize novel switch combinations for various bio-application areas.
  • Activator Ligands – We maintain an extensive library of previously designed activator ligands that can be tested with various RheoSwitch® combinations plus the ability to perform ongoing research related to new classes of switch activators.
  • Synthetic Promoters – The RheoSwitch® architecture is designed for employment of either one or two switch promoters. These promoter positions can be modified to contain natural or synthetic conditional promoters that will activate and deactivate based on real-time intracellular factors. This in turn offers an opportunity to regulate the inducible transcription domain with both an externally applied activator ligand plus the real-time feedback of factors related to the desired expression outcomes. We are designing and testing novel synthetic promoters for prospective use in our RheoSwitch® system and related bio-applications.
  • Transgene Manufacturing – We continue our industry-leading research into advancements in the time-to-completion, size, and complexity of transgene manufacturing, including ongoing efforts to enhance our de novo synthesis capabilities and protocols.
  • Protein Decoys – We are designing and improving mutant protein "decoys" that function as antagonists against targeted extracellular or intracellular protein-protein interactions.
  • Subcellular LocSigs – The nano-geography of subcellular space is highly relevant to the successful modulation of intracellular protein-protein interactions and the avoidance of undesirable "off-location" effects. We continue to perform research related to the design and discovery of novel subcellular localization signals and their combination with protein decoys.
  • Multi-Species Adaptations – Specific DNA control and effector components are being adapted for use in non-mammalian species, and specifically as part of our efforts related to high yield production of human proteins and industrial enzymes, plus extension into non-mammalian areas of agbio.
  • Transgene Delivery – We are continually collaborating on the best techniques and strategies for delivery of our transgenes, for both ex vivo and in vivo applications. This includes both conventional and novel delivery modalities.
  • Multigenic Systems – Solutions to foremost challenges increasingly require the design and testing of multiple transgenes working in concert as an integrated transgene system or network. We continue to make significant advancements in this area using our UltraVector® architecture and robust UltraVector®-enabled component library.